Jounce Therapeutics, an early-stage biotech developing T cell immuno-oncology therapies with Celgene, raised $102 million by offering 6.4 million shares at $16, above the range of $13 to $15. Jounce Therapeutics plans to list on the Nasdaq under the symbol JNCE. J.P. Morgan and Cowen & Company acted as lead managers on the deal.
